Dr Nigam agrees to doubling slick NW6/NW7

[UK_]

This is all just hopeful speculation. Just because Dr Mwamba visited Dr Nigam's lab doesn't mean anything. It just shows that Dr Mwamba is open minded and not that Dr Nigam's technique work. Until we see photographic proof that there is significant regeneration, we shouldn't have this "Dr Nigam lets put all our hopes into his basket" mentality.

I seriously doubt that one small lab can do what million dollar companies haven't been able to, especially since Dr Nigam only got into hair transplant industry 2 years ago. If it sounds too good to be true then it probably is. That is not to say I don't hope its true, but we have to be logical.

That's not what I was saying, I stated that [although there is little evidence] I personally feel Dr Nigam has really shook up the hair loss industry, and you are actually wrong, Dr Mwamba has stated in emails, on forum posts and even an interview with SPENCER that Nigam is "on to something" - Dr Mwamba spent a lot of time with Nigam and even left one of his assistants behind with Nigam for a while.

Use some common sense - why would someone who is trying to mislead people invite an IAHRS surgeon to his clinic to evaluate the work? Has that ever happened in the past?

[greatjob!]

You guys are both right. Yes, of course the ultimate goal is to hit the homerun and sell it to a big pharma for example. But as long as a startup can convince investors to put more money into their company, they have an incentive to keep muddling on even when they know they will never get to something. You see the same thing in some public traded companies. They keep offering shares, stock price tanks and when it gets too low, they reverse split. Meanwhile management keeps paying themselves good salaries, plus, more importantly, they keep giving themselves stockbonuses and sell those to the market.

I think there is a definite difference between biotech companies that are private and public. My statement applies more to privately owned and funded companies, their motivation is more to develop a treatment and sell it as quickly as possible. Whereas publicly owned companies are more inclined to dick around, like Replicel for example. All the people that got so excited and bought their stock last year fell into their trap. Even if the company is a success they would no doubt reverse split to raise their price and get listed on a major market and all those people that bought stock would be royally screwed no matter what. It was quite comical watching that replicel stock thread a while back with all the people thinking they could make 10 grand off the stock to pay for their procedure.

[HairBane]

Dr. Nigam will achieve Gandhi-level fame in India if he can beat all the biotech companies to a cure with doubling and HM. I'm impressed with how open he's being about everything.

Question for Nigam: Do you keep up to date with what Histogen, Follica, Replicel etc. are doing with their trials and patents? You could quite easily replicate some of their ideas and integrate them into your therapies to get the complete treatment with the relaxed stem cell laws in India, no?

[crafter]

speculation speculation speculation. I await good photographic evidence that is assessed by other surgeons.

[Arashi]

This is all just hopeful speculation. Just because Dr Mwamba visited Dr Nigam's lab doesn't mean anything. It just shows that Dr Mwamba is open minded and not that Dr Nigam's technique work. Until we see photographic proof that there is significant regeneration, we shouldn't have this "Dr Nigam lets put all our hopes into his basket" mentality.

I seriously doubt that one small lab can do what million dollar companies haven't been able to, especially since Dr Nigam only got into hair transplant industry 2 years ago. If it sounds too good to be true then it probably is. That is not to say I don't hope its true, but we have to be logical.

This. +100000.

[didi]

This is all just hopeful speculation. Just because Dr Mwamba visited Dr Nigam's lab doesn't mean anything. It just shows that Dr Mwamba is open minded and not that Dr Nigam's technique work. Until we see photographic proof that there is significant regeneration, we shouldn't have this "Dr Nigam lets put all our hopes into his basket" mentality.

I seriously doubt that one small lab can do what million dollar companies haven't been able to, especially since Dr Nigam only got into hair transplant industry 2 years ago. If it sounds too good to be true then it probably is. That is not to say I don't hope its true, but we have to be logical.

Agree with locke999

Aderans had all the money, time and scientists needed and they failed. Dr Nigam comes out of nowhere and claims to double donor at 100% regeneration rate which is virtually unlimited donor. Yet his technique is surprisingly simple and had more than 1 year to convince us.

Dr Mwambas visit don't mean much, lets see if he can replicate it in his clinic.

BTW, Nigams invivo is exactly the same as Ghos HST, and we saw how that went.


TBH,I have more faith in pilofocus

[drnigams]

Great job ,arashi..
I wish to do the same.
Sell my, cellular tissue engineered doubling techniques...
to various surgeons across the globe with local exclusivity...lets see..how it unfolds..
Greatjob and arashi...your financial wisdom is welcome.... as you two guys seem to know much about equity and investors...

BTW...the nw7 new case equally as impressive as thane..is coming to start the nw7 conversion from this saturday..will post pics on monday..

The malaysian indian guy had come for his hm injection yesterday... who had also taken one doubling session in 1st week of may 2013(his baldness grade and donor was worse than thane patient...in april)...has improved donor...and early growth of bisected follicles...i have taken his pics and video...will post soon...
OFF late i have started injecting more of hm and dp injections at donor too..and i am seeing a lot of patients saying thier donor is thicker now...as we know donor is a non aga scalp...may respond better...

This is a completely false statement. When you work for a start-up biotech company you make very little in terms of salary, most compensation is paid out in ownership and stock options. The incentive in working for a biotech start-up is to develop something that can be sold to big pharma and cash in a big pay day. What your claiming is the exact opposite of what the reality is in the industry.

[locke999]

Personally, I know we havent seen much evidence for our own eyes, but I think Nigam has really shook up the hair transplant sector - the fact that Dr Mwamba an IAHRS surgeon went to see and LEARN his technique is partial evidence of this... even Dr Cole was interested, I bet behind the scenes a lot of surgeons are following what Nigam is doing.

This is all just hopeful speculation. Just because Dr Mwamba visited Dr Nigam's lab doesn't mean anything. It just shows that Dr Mwamba is open minded and not that Dr Nigam's technique work. Until we see photographic proof that there is significant regeneration, we shouldn't have this "Dr Nigam lets put all our hopes into his basket" mentality.

I seriously doubt that one small lab can do what million dollar companies haven't been able to, especially since Dr Nigam only got into hair transplant industry 2 years ago. If it sounds too good to be true then it probably is. That is not to say I don't hope its true, but we have to be logical.

[UK_]

You guys are both right. Yes, of course the ultimate goal is to hit the homerun and sell it to a big pharma for example. But as long as a startup can convince investors to put more money into their company, they have an incentive to keep muddling on even when they know they will never get to something. You see the same thing in some public traded companies. They keep offering shares, stock price tanks and when it gets too low, they reverse split. Meanwhile management keeps paying themselves good salaries, plus, more importantly, they keep giving themselves stockbonuses and sell those to the market.

Personally, I know we havent seen much evidence for our own eyes, but I think Nigam has really shook up the hair transplant sector - the fact that Dr Mwamba an IAHRS surgeon went to see and LEARN his technique is partial evidence of this... even Dr Cole was interested, I bet behind the scenes a lot of surgeons are following what Nigam is doing.

[TO YOUNG TO RETIRE]

what do you mean by that? it is safe already

And from that it will take a full year to know if its safe!

[Artha]

Supposedly he'll start with Thane this monday.

And from that it will take a full year to know if its safe!

[TO YOUNG TO RETIRE]

i suppose we will get pics....

Supposedly he'll start with Thane this monday.

[Arashi]

Alright, just dropping in for the update. Has this started yet? The doubling procedures?

Supposedly he'll start with Thane this monday.

[JDW]

Alright, just dropping in for the update. Has this started yet? The doubling procedures?

[Arashi]

This is a completely false statement. When you work for a start-up biotech company you make very little in terms of salary, most compensation is paid out in ownership and stock options. The incentive in working for a biotech start-up is to develop something that can be sold to big pharma and cash in a big pay day. What your claiming is the exact opposite of what the reality is in the industry.

You guys are both right. Yes, of course the ultimate goal is to hit the homerun and sell it to a big pharma for example. But as long as a startup can convince investors to put more money into their company, they have an incentive to keep muddling on even when they know they will never get to something. You see the same thing in some public traded companies. They keep offering shares, stock price tanks and when it gets too low, they reverse split. Meanwhile management keeps paying themselves good salaries, plus, more importantly, they keep giving themselves stockbonuses and sell those to the market.